Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery Opens at Gladstone Institutes
The Thermo Fisher Scientific Proteomics Facility for Disease Target Discovery opened at the Gladstone Institutes (San Francisco, California) on June 24, as part of a collaboration between Thermo Fisher (San Jose, California), Gladstone, the University of California, San Francisco (UCSF), and QB3 (San Francisco, California), to accelerate targeted proteomics research using advanced mass spectrometry techniques.
The facility is directed by Nevan J. Krogan, PhD, a senior investigator at the Gladstone Institutes, a professor of cellular and molecular pharmacology at UCSF, and director of the UCSF division of the life science research institute and startup accelerator QB3. The facility will provide scientists from Gladstone, UCSF, and QB3 with state-of-the-art mass spectrometry technologies to characterize protein dynamics in complex biological systems. The technologies will enable scientists to acquire knowledge about the interactions between genes and the proteins they produce, and help facilitate solutions to unanswered biomedical problems.
Among the various approaches available in the facility are the creation of high-resolution protein-protein interaction maps and advanced protein characterization, genome-directed proteomic screening and selection, and ultra-sensitive, quantitative analysis of protein abundance and post-translational modifications.
In addition to enabling innovative research, the Thermo Fisher facility will be a focal point for promoting biological applications of mass spectrometry by hosting an invited lecture series, discussion groups, workshops, and trainings.
Presenting GC Data Comparisons to Laypersons to Understand Potential Courtroom Implications
January 6th 2025In forensic science, scientific testimony is routinely presented in court to juries who may have limited or no scientific background, putting law enforcement and defense personnel in the position of having to make rapid decisions in short timeframes based on findings of which they are not specialists. Katelynn Perrault Uptmor, Assistant Professor of Chemistry at William & Mary (Williamsburg, Virginia) believes that the introduction of new technologies into the framework of routine forensic analysis must therefore bridge the gap between introduction of new and novel analytical science and the communication of that science to a court of law, and that analytical chemistry research must be mindful of the need to fill this gap in promoting new technologies.
Detailed Glycosylation Analysis of Therapeutic Enzymes Utilizing Comprehensive 2D-LC–MS
January 3rd 2025In this article, the use of comprehensive two-dimensional liquid chromatography (LC×LC) coupled to mass spectrometry (MS) for characterizing glycosylation of therapeutic enzymes is presented.
Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.
